Selenium disulfide: a key ingredient to rebalance the scalp microbiome and sebum quality in the management of dandruff.

Cutibacterium Malassezia Staphylococcus scalp microbiota scalp squalene selenium disulfide

Journal

European journal of dermatology : EJD
ISSN: 1952-4013
Titre abrégé: Eur J Dermatol
Pays: France
ID NLM: 9206420

Informations de publication

Date de publication:
01 Mar 2023
Historique:
medline: 28 4 2023
pubmed: 26 4 2023
entrez: 26 4 2023
Statut: ppublish

Résumé

Dandruff is a chronic and relapsing scalp condition characterized by flaky scalp. Environmental and host factors (exposome) may alter the sebaceous gland activity, sebum composition, epidermal barrier function, and scalp microbiome balance, resulting in dandruff. Selenium disulfide (SeS2) improves the clinical signs of dandruff. To investigate the mode of action of SeS2 shampoo during treatment and relapse phases. Two single-center studies assessed dandruff severity, subjective efficacy perception, microbial balance, microbiota diversity and sebum lipids. SeS2 significantly (p≤0.01) reduced scaling and led to a significant decrease of Malassezia and Staphylococcus spp. counts in both lesional and non-lesional areas, compared to the vehicle at D28 returning to baseline levels at D56. Cutibacterium spp. levels were not different between the SeS2 and the vehicle treatment groups but had significantly increased with SeS2 (p<0.001) in the lesional zone at D56. The ratio Malassezia spp./Cutibacterium spp. decreased significantly in lesional zones compared to baseline levels, at both D28 and D35 (p<0.001). The total squalene content significantly increased (p<0.05), whereas peroxided squalene had significantly decreased by almost 50% at D31. The ratio triglycerides/free fatty acids significantly (p<0.0001) increased, almost 5-fold, between D0 and D31. SeS2 shampoo was very well tolerated. SeS2 is beneficial in scalp dandruff, even after treatment interruption. It is well tolerated, rebalances the equilibrium between the main bacterial and fungal populations, and improves sebum quality.

Sections du résumé

BACKGROUND BACKGROUND
Dandruff is a chronic and relapsing scalp condition characterized by flaky scalp. Environmental and host factors (exposome) may alter the sebaceous gland activity, sebum composition, epidermal barrier function, and scalp microbiome balance, resulting in dandruff. Selenium disulfide (SeS2) improves the clinical signs of dandruff.
OBJECTIVES OBJECTIVE
To investigate the mode of action of SeS2 shampoo during treatment and relapse phases.
MATERIALS & METHODS METHODS
Two single-center studies assessed dandruff severity, subjective efficacy perception, microbial balance, microbiota diversity and sebum lipids.
RESULTS RESULTS
SeS2 significantly (p≤0.01) reduced scaling and led to a significant decrease of Malassezia and Staphylococcus spp. counts in both lesional and non-lesional areas, compared to the vehicle at D28 returning to baseline levels at D56. Cutibacterium spp. levels were not different between the SeS2 and the vehicle treatment groups but had significantly increased with SeS2 (p<0.001) in the lesional zone at D56. The ratio Malassezia spp./Cutibacterium spp. decreased significantly in lesional zones compared to baseline levels, at both D28 and D35 (p<0.001). The total squalene content significantly increased (p<0.05), whereas peroxided squalene had significantly decreased by almost 50% at D31. The ratio triglycerides/free fatty acids significantly (p<0.0001) increased, almost 5-fold, between D0 and D31. SeS2 shampoo was very well tolerated.
CONCLUSION CONCLUSIONS
SeS2 is beneficial in scalp dandruff, even after treatment interruption. It is well tolerated, rebalances the equilibrium between the main bacterial and fungal populations, and improves sebum quality.

Identifiants

pubmed: 37098773
pii: ejd.2023.4400
doi: 10.1684/ejd.2023.4400
doi:

Substances chimiques

selenium disulfide Z69D9E381Q
Squalene 7QWM220FJH

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5-12

Auteurs

Cécile Clavaud (C)

L'Oréal Research & Innovation, Aulnay-sous-Bois, France.

Céline Michelin (C)

L'Oréal Research & Innovation, St-Ouen, France.

Sayeh Pourhamidi (S)

L'Oréal Research & Innovation, Aulnay-sous-Bois, France.

Sarah Ziane (S)

L'Oréal Research & Innovation, St-Ouen, France.

Charles El Rawadi (C)

L'Oréal Research & Innovation, Aulnay-sous-Bois, France.

Benoit Muller (B)

L'Oréal Research & Innovation, St-Ouen, France.

Luc Souverain (L)

L'Oréal Research & Innovation, Aulnay-sous-Bois, France.

Ségolène Panhard (S)

L'Oréal Research & Innovation, Aulnay-sous-Bois, France.

Roland Jourdain (R)

L'Oréal Research & Innovation, Aulnay-sous-Bois, France.

Philippe Massiot (P)

L'Oréal Research & Innovation, St-Ouen, France.

Richard Martin (R)

L'Oréal Research & Innovation, Aulnay-sous-Bois, France.

Olivia Isard (O)

L'Oréal Research & Innovation, St-Ouen, France.

Fabien Cabirol (F)

L'Oréal Research & Innovation, Aulnay-sous-Bois, France.

Damien Drillon (D)

L'Oréal Research & Innovation, Aulnay-sous-Bois, France.

Lionel Breton (L)

L'Oréal Research & Innovation, Aulnay-sous-Bois, France.

Florence Pouradier (F)

L'Oréal Research & Innovation, St-Ouen, France.

Luc Aguilar (L)

L'Oréal Research & Innovation, Aulnay-sous-Bois, France.

Geneviève Loussouarn (G)

L'Oréal Research & Innovation, St-Ouen, France.

Audrey Gueniche (A)

L'Oréal Research & Innovation, Chevilly La Rue, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH